Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction
Authors:
- Fernando MingolFMFernando Mingol
- Javier GallegoJGJavier Gallego
- Albina OrduñaAOAlbina Orduña
- Amparo Martinez-BlascoAMAmparo Martinez-Blasco
- Javier Sola-VeraJSJavier Sola-Vera
- Pedro MoyaPMPedro Moya
- Miguel Angel MorcilloMMMiguel Angel Morcillo
- Juan Antonio RuizJRJuan Antonio Ruiz
- Rafael CalpenaRCRafael Calpena
- Francisco-Javier LacuevaFLFrancisco-Javier Lacueva
Open Access
- 22 May 2015
- journal article
- research article
- Published by Springer Nature in BMC Surgery
- Vol. 15 (1) , 1-10
Abstract
We assessed the effectiveness of perioperative MAGIC-style chemotherapy in our series focused on the tumor regression grade and survival rate. We conducted a retrospective study of 53 patients following a perioperative regimen of epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/X). Forty-four (83 %) neoplasias were located in the stomach and 9 (17 %) were located at the esophagogastric junction. Perioperative chemotherapy completion, resection, TNM staging, the tumor regression grade (Becker’s classification) and survival were analyzed. Forty-five patients (85 %) completed the 3 preoperative cycles. R0 resection was achieved in 42 (79 %) patients. Thirty-five (66 %) patients completed the 3 postoperative cycles. Nine carcinomas (17 %) were considered major responders after preoperative chemotherapy. With multivariate analysis, only completion of perioperative chemotherapy (HR: 0.25; 95%CI: 0.08 – 0.79; p = 0.019) was identified as an independent prognostic factor for disease-specific survival. However, the protective effect of perioperative therapy was lost in patients with ypT3-4 and more than 4 positive lymph nodes (HR: 1.16; 95%CI: 1.02 – 1.32; p = 0.029). The tumor regression grade (major vs minor responders) was at the limit of significance only with univariate analysis. The 5-year overall and disease-specific survival rates were 18 % and 22 % respectively. The percentage of major responder tumors after preoperative chemotherapy was low. Completion of perioperative ECF/X chemotherapy may benefit patients with gastric carcinomas that do not invade the subserosa with few positive lymph nodes.Keywords
This publication has 32 references indexed in Scilit:
- Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer ResectionJournal of Clinical Oncology, 2012
- Adjuvant Radiation Therapy Increases Overall Survival in Node-Positive Gastric Cancer Patients With Aggressive Surgical Resection and Lymph Node DissectionAmerican Journal of Clinical Oncology, 2012
- Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST TrialJournal of Clinical Oncology, 2012
- Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric CancerJournal of Clinical Oncology, 2011
- Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trialThe Lancet Oncology, 2010
- Operative mortality after gastric cancer resection and long-term survival differences across EuropeBritish Journal of Surgery, 2010
- Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trialBritish Journal of Cancer, 1999
- Relevant Prognostic Factors in Gastric CancerAnnals of Surgery, 1998
- Lymph Node Metastases of Gastric CancerAnnals of Surgery, 1989